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OSTEOGENESIS AND SUPPRESSES THE PROGRESSION OF
SECONDARY OA IN A RABBIT MODEL OF OSTEONECROSIS
OF THE FEMORAL HEAD
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Purpose: Untreated symptomatic osteonecrosis of the femoral head
(ONFH) often leads to femoral head collapse and advanced secondary
osteoarthritis (OA). The primary goal in the treatment of ONFH is to treat
it in early enough stage to preserve the femoral head and avoid total
hip arthroplasty. The use of growth factors have been proposed. The
purpose of this paper is to evaluate the effects of basic ﬁbroblast growth
factor (bFGF) on the repair of ONFH in rabbits.
Methods: To evaluate the in vivo effect of implanted bFGF, we created drill
hole (1mm in diameter and 5mm in depth) in the femoral head of rabbit
ONFH model. Animal model were induced by the treatment combining
the administration of high dose corticosteroids (40mg/kg of methylpred-
nisolone) and capsule resection, accompanied by coagulating of the soft-
tissue attachments from femoral surgical neck and acetabulum. 8 weeks
after induction of ONFH, we implanted gelatin hydrogel microspheres con-
taining 100mg bFGF or PBS into the femoral head and articular surface.
Thirty-ﬁve male Japanese white rabbits underwent ONFH were divided
three groups as follows: (1) Control group, in which the rabbits received
no further treatment after ONFH; (2) PBS group, in which 8 weeks after
ONFH, PBS contained in gelatin hydrogel microspheres were directly
injected; (3) bFGF group, in which 8 weeks after ONFH, 100mg bFGF
contained in gelatin hydrogel microspheres were directly injected. The
right hip was experimented on in all treated rabbits. Animals in control
group were killed at 0, 4, 8, 12, 24 weeks after ONFH (n= 5 each).
Animals in the treatment groups were killed at 24 weeks after ONFH
(n= 5). Gross morphologic and histologic examinations, and radiographic
assessment by micro CT scans were performed.
Results: Injections of bFGF contained in gelatin hydrogel microspheres
suppressed the progression of OA in the ONFH rabbit model. Macroscop-
ically, the area of articular surface of the right femoral head involved OA
change was signiﬁcantly less in the bFGF group (14.1±9.0%) compared
with the PBS group (42.1±5.4%, P <0.01) or control group (62.5±11.4%,
P <0.01). The roundness index of the right femoral head was signiﬁ-
cantly less in the bFGF group (52.4±4.9%) than that in the PBS group
(62.2±4.3%, P < 0.05) Radiographic assessment by micro CT scans
showed signiﬁcantly better preservation of the femoral head structure and
better osteogenesis in the bFGF group compared with the PBS group
or control group. The irregularity of subchondral bone of the femoral
head in the bFGF group (17.5±6.6%) was less than that in the PBS
group (59.1±13.6%, P <0.01) or control group (54.2±10.7%, P <0.01).
Bone formation rate of/around implant area was signiﬁcantly higher in the
bFGF group (71.2±3.3%, 37.9±11.5%) compared with the PBS group
(47.8±8.6%, 11.5±4.2%, P <0.01). According to the modiﬁed Mankin’s
histological score, the severity of OA in the bFGF group (3.4±1.6) was
signiﬁcantly less than that in the PBS group (8.8±2.6, P < 0.01) or control
group (7.8±0.4, P <0.05).
Conclusions: To our knowledge, this is the ﬁrst study to show that bFGF
induces osteogenesis and suppresses the progression of secondary OA
in the ONFH animal model. Our ﬁndings demonstrated that bFGF into the
femoral head and articular surface had therapeutic effects on secondary
OA development in the ONFH. Our results suggest the potential feasibility
of a new conservative treatment for ONFH.
77 ASSOCIATION OF OSTEOCHONDRAL ANGIOGENESIS,
CARTILAGE LESION AND BEHAVIOURAL PAIN IN A RAT
MODEL OF OSTEOARTHRITIS
J. Bowyer1, R. Webster1, R.A. Maciewicz1, P. Mapp2, D.A. Walsh2.
1AstraZeneca, Macclesﬁeld, UNITED KINGDOM, 2Academic
Rheumatology, University of Nottingham, City Hospital, Nottingham,
UNITED KINGDOM
Purpose: We have previously demonstrated chondro-protection and re-
duced weight-bearing asymmetry with a Matrix Metalloproteinase inhibitor
(MMPi) in the rat meniscal transection (MNX) model of osteoarthritis (OA).
The purpose of the current study was to elucidate the analgesic mech-
anism of the MMPi by investigating angiogenesis at the osteochondral
junction (OCJ) as a surrogate of nerve growth.
Methods: This was a convenience study of an experiment that assessed
the effect of an MMPi in the MNX model of OA, the results of which
have been reported previously. Brieﬂy, pathology was induced in male
Lewis rats, (n = 10/group) (270 g, Harlan, UK) by transecting the medial
collateral ligament and making a full thickness cut through the meniscus
(day 0). Sham (SHAM) animals underwent the same procedure with
omission of the meniscus transection. MNX animals were dosed orally
with vehicle (HPMC/tween, 1%DMSO) or an equipotent MMP 2, 8, 9, 13
inhibitor (0.125, 0.5, and 2.5mg/kg twice per day). Rats were sacriﬁced
35 days post surgery. Angiogensis was assessed by counting the blood
vessels crossing the OCJ of the medial tibial plateaux in at least three
central sections per case and an arithmetic mean determined for each
animal. Geometric means were then calculated for each group of 10
animals and were analysed by 1 way ANOVA with Bonferroni corrections
for multiple comparisons. Correlations between the angiogenesis and
weight bearing asymmetry (assessed using an incapacitance meter) and
cartilage lesions (assessed by toluidine blue stained coronal step sections
across the entire knee joint) were undertaken.
Results: Blood vessels crossing the OCJ were elevated in the in MNX
animals (mean 7.1, C.I 8.2−6.1) versus the SHAM treated animals
(mean 1.0, CI 1.4−0.6) (p< 0.001). The angiogenesis observed in the
MNX animals was reduced by treatment with MMPi 2.5mg/kg (mean 2.1,
CI 2.8−1.3; mean difference 5.0, CI 6.2−3.8) and 0.5mg/kg (mean 4.2, CI
4.6−3.8; mean difference 2.9, CI.4.1−1.6), (both p< 0.001). At the highest
dose the number of vessels crossing the OCJ was not different (p> 0.05)
from the SHAM treated controls (mean 1.0, CI 0.6−1.4; mean difference
1.0, CI −0.1−2.3). The correlation between vessels crossing the OCJ
and dose of MMPi (Spearman’s correlation −0.892, p< 0.001), was found
to be independent of cartilage lesion score using partial correlations.
Amelioration of the asymmetrical weight bearing in the MNX animals by
treatment with the MMPi was found to correlate (Spearman’s correlation
−0.52, p< 0.001) with the reduction of vessels crossing the OCJ.
Conclusions: Cartilage is usually thought to be an avascular and aneu-
ronal tissue although in human disease such as OA there is known to
be vascular and neuronal activity in the junction between cartilage and
bone. Here we show that there is vascular penetration in a rat surgical
model of OA and that treatment with an MMPi is associated with reduction
in osteochondral angiogenesis and supports the anti-angiogenic effects
observed with MMP inhibitors in other pre-clinical models. The correlation
between angiogenesis and behavioural pain in the MMPi treated group
may be explained by the fact that angiogenesis correlates with new nerve
growth in human and rat tissues. These data suggest that agents, which
target angiogenic mechanisms, may have utility in the treatment of pain
associated with osteoarthritis.
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Purpose: This study was designed to evaluate the reproducibility of
spontaneous knee osteoarthritis (OA) in STR/ort mice and to determine
the potential utility of this model to test therapeutics aimed at disease-
modiﬁcation of OA.
Methods: Two trios of STR/ort mice were obtained from the Imperial
College, London and the colony rederived for internal studies. Mice were
group-housed with up to 5 single-sex mice/cage and allowed free-access
to food and water on an IACUC-approved protocol. At 6−8 wks of age,
mice were provided custom feed incorporating vehicle or 50mg/kg/day of
a broad-spectrum MMP inhibitor (MPI-369). Three groups of 20−22 mice
were evaluated in this study: vehicle treated males and females, and
MPI-369 treated males with 20−22 mice/group. Mice were euthanized at
12 months of age and plasma harvested for pharmacokinetic analysis.
